MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 150009 | Name: TH-EGO

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TH-EGO is a antiviral agent and is a synthetic strigolactone or SL. The TH-EGO agent impairs β-coronavirus replication including SARS-CoV-2 and the common cold human coronavirus HCoV-OC43.

Chemical Structure

TH-EGO
TH-EGO
CAS#N/A

Theoretical Analysis

MedKoo Cat#: 150009

Name: TH-EGO

CAS#: N/A

Chemical Formula: C22H17NO4S

Exact Mass: 391.0878

Molecular Weight: 391.44

Elemental Analysis: C, 67.50; H, 4.38; N, 3.58; O, 16.35; S, 8.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
TH-EGO; THEGO; TH EGO;
IUPAC/Chemical Name
(R,E)-4-Methyl-2-(((4-methyl-5-oxo-2,5-dihydrofuran-2-yl)oxy)methylene)-7-(thiophen-2-yl)-1,4-dihydrocyclopenta[b]indol-3(2H)-one
InChi Key
GGLOBOZIRBGSSF-FIIODCPWSA-N
InChi Code
1S/C22H17NO4S/c1-12-8-19(27-22(12)25)26-11-14-10-16-15-9-13(18-4-3-7-28-18)5-6-17(15)23(2)20(16)21(14)24/h3-9,11,19H,10H2,1-2H3/b14-11+/t19-/m1/s1
SMILES Code
O=C(C(N1C)=C2C3=C1C=CC(C4=CC=CS4)=C3)/C(C2)=C/O[C@@H](C=C5C)OC5=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 391.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Biolatti M, Blangetti M, Baggieri M, Marchi A, Gioacchini S, Bajetto G, Arnodo D, Bucci P, Fioravanti R, Kojouri M, Bersani M, D'Arrigo G, Siragusa L, Ghinato S, De Andrea M, Gugliesi F, Albano C, Pasquero S, Visentin I, D'Ugo E, Esposito F, Malune P, Tramontano E, Prandi C, Spyrakis F, Magurano F, Dell'Oste V. Strigolactones as Broad-Spectrum Antivirals against β-Coronaviruses through Targeting the Main Protease Mpro. ACS Infect Dis. 2023 Jul 14;9(7):1310-1318. doi: 10.1021/acsinfecdis.3c00219. Epub 2023 Jun 26. PMID: 37358826. 2: Britt, W.J.; Prichard, M.N. New therapies for human cytomegalovirus infections. Antiviral Res. 2018, 159, 153–174. [Google Scholar] [CrossRef] Zwanenburg, B.; Blanco-Ania, D. Strigolactones: New plant hormones in the spotlight. J. Exp. Bot. 2018, 69, 2205–2218. [Google Scholar] [CrossRef] [PubMed] 3: Koltai, H.; Prandi, C. Strigolactones: Past, present and future. Planta 2016, 243, 1309. [Google Scholar] [CrossRef] [Green Version] Makhzoum, A.; Yousefzadi, M.; Malik, S.; Gantet, P.; Tremouillaux-Guiller, J. Strigolactone biology: Genes, functional genomics, epigenetics and applications. Crit. Rev. Biotechnol. 2017, 37, 151–162. [Google Scholar] [CrossRef] 4: Mayzlish-Gati, E.; Laufer, D.; Grivas, C.F.; Shaknof, J.; Sananes, A.; Bier, A.; Ben-Harosh, S.; Belausov, E.; Johnson, M.D.; Artuso, E.; et al. Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model. Cancer Biol. Ther. 2015, 16, 1682–1688. [Google Scholar] [CrossRef] [Green Version] 5: Hasan, M.N.; Razvi, S.S.I.; Kuerban, A.; Balamash, K.S.; Al-Bishri, W.M.; Abulnaja, K.O.; Choudhry, H.; Khan, J.A.; Moselhy, S.S.; M, Z.; et al. Strigolactones-a novel class of phytohormones as anti-cancer agents. J. Pestic. Sci. 2018, 43, 168–172. [Google Scholar] [CrossRef] Hasan, M.N.; Choudhry, H.; Razvi, S.S.; Moselhy, S.S.; Kumosani, T.A.; Zamzami, M.A.; Omran, Z.; Halwani, M.A.; Al-Babili, S.; Abualnaja, K.O.; et al. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells. Bioorg. Med. Chem. Lett. 2018, 28, 1077–1083. [Google Scholar] [CrossRef] [Green Version] 6: Pollock, C.B.; McDonough, S.; Wang, V.S.; Lee, H.; Ringer, L.; Li, X.; Prandi, C.; Lee, R.J.; Feldman, A.S.; Koltai, H.; et al. Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells. Oncotarget 2014, 5, 1683–1698. [Google Scholar] [CrossRef] [PubMed] [Green Version]

View History

TGFβRI-IN-3

TGFβRI-IN-3

Featured